Publications
392
Citations
4,921
Est. group size
~62
Recurring co-author estimate
Active years
35
Publishing since 1992
Robert Wesolowski's work focuses on the clinical treatment of breast cancer, especially hormone receptor-positive and HER2-negative advanced/metastatic disease. His research includes early- and late-phase clinical trials of new drugs (such as PI3K, CDK4/6, and RSK inhibitors) often combined with hormone therapies, as well as studies on managing bone metastases and reducing side effects of chemotherapy. Much of this work is conducted through multi-site collaborative clinical trials reported in oncology journals.
Publication output grew substantially from 2017 through a peak around 2023-2024, then shows a decline in 2025 and limited 2026 data reflecting the partial year.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Denosumab as Second-Line Treatment in Patients With Metastatic Breast Cancer: A Retrospective Descriptive Pilot Study From a Single Institution
Cancer Control · 2026
- Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions
Frontiers in Oncology · 2026
- Safely Stopping Premedications in Patients Receiving Paclitaxel: A Randomized Trial
Journal of the National Comprehensive Cancer Network · 2026
- Artificial Intelligence in Breast Pathology: Recent Advances in Multimodal Models, Explainability, and Clinical Applications
Journal of Clinical and Translational Pathology · 2026
- Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy
The Lancet Oncology · 2025
- Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Clinical Cancer Research · 2025
- LBA17 Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1
Annals of Oncology · 2025
- Abstract PS7-02: First-in-human results of STX-478, a mutant-selective PI3K alpha inhibitor, in HR+ breast cancer and advanced solid tumor patients
Clinical Cancer Research · 2025
- Abstract P4-10-20: First-in-human phase 1a, dose-escalation study of BGB-43395 (CDK4-selective inhibitor) as monotherapy and in combination with fulvestrant or letrozole in patients with metastatic HR+/HER2+ breast cancer and other advanced solid tumors
Clinical Cancer Research · 2025
- Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses Pulmonary Arterial Hypertension, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression
The Thoracic and Cardiovascular Surgeon · 2025
- HSR25-154: Treatment Patterns and Prognosis of Patients With HER2-Negative Early Breast Cancer and Germline Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2
Journal of the National Comprehensive Cancer Network · 2025
- Dauntless-1, a phase 2 clinical trial to evaluate PMD-026, a first-in-class pan-RSK inhibitor, combined with fulvestrant to overcome resistance to CDK4/6 inhibitors in advanced or metastatic HR+/HER2- breast cancer.
Journal of Clinical Oncology · 2025
- Abstract P4-08-25: Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy
Clinical Cancer Research · 2025
- Figure 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2025
- Table 3 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2025
- Journal of Clinical Oncology×52
- Cancer Research×45
- Clinical Cancer Research×10
- Annals of Oncology×9
- Journal of the National Comprehensive Cancer Network×7
- Preeti Sudheendra
Medicine · The Ohio State University
- Sagar Sardesai
Medicine · The Ohio State University
- Gilbert Bader
Medicine · The Ohio State University
- Patrick Schnell
Medicine · The Ohio State University
- Sarah Khan
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile